viral
hepat
remain
signific
worldwid
threat
spite
avail
sever
success
therapeut
vaccin
strategi
complic
associ
acut
chronic
infect
liver
failur
cirrhosi
hepatocellular
carcinoma
caus
consider
morbid
mortal
given
signific
burden
healthcar
system
caus
viral
hepat
essenti
novel
effect
therapeut
develop
present
review
attempt
summar
current
treatment
viral
hepat
provid
outlin
upcom
promis
new
therapeut
develop
novel
therapeut
requir
understand
viral
life
cycl
viral
effector
molecular
detail
review
also
discuss
virallyencod
effector
found
essenti
viru
surviv
replic
host
milieu
may
util
potenti
candid
develop
altern
therapi
futur
hepat
medic
condit
wherein
liver
undergo
inflamm
due
plethora
reason
includ
drug
abus
excess
alcohol
abus
diseas
condit
etc
inflamm
manifest
symptom
jaundic
nausea
abdomin
pain
malais
etc
caus
viral
infect
condit
refer
viral
hepat
five
hepatotrop
virusesnam
hepat
b
c
e
virusestarget
liver
cell
human
caus
acut
chronic
hepat
addit
virus
adenoviru
cytomegaloviru
cmv
epsteinbarr
viru
ebv
occasion
caus
symptom
hepat
acut
infect
healthi
immunocompet
individu
clear
spontan
complic
like
cirrhosi
hepatocellular
carcinoma
hcc
fulmin
hepat
failur
fhf
may
aris
immunocompromis
individu
due
associ
secondari
reason
exist
infect
alcohol
abus
genet
predisposit
hcc
third
lead
caus
cancerrel
death
worldwid
close
associ
hepat
b
viru
hbv
infect
even
though
therapeut
strategi
devis
till
date
target
toward
chronic
infect
treatment
option
becom
sever
limit
advanc
stage
patient
addit
current
medic
signific
sideeffect
pose
issu
diseas
manag
henc
urgent
requir
safer
potent
drug
review
focu
therapeut
current
avail
treat
viral
hepat
form
addit
potenti
new
therapeut
target
inhibitorbas
therapi
viral
membranepenetr
peptid
viroporin
group
viral
encod
protein
involv
facilit
replic
specif
step
viral
life
cycl
also
discuss
life
cycl
known
hepatotrop
virusesparticularli
b
c
ehav
studi
signific
detail
although
lack
appropri
cell
cultur
system
slowgrow
natur
viru
hamper
studi
consider
inform
avail
entri
replic
exit
mechan
virus
specif
hostinteract
partner
viru
hepat
viru
hav
thought
associ
cellsurfac
protein
receptor
hepat
viru
cellular
receptor
immunoglobulin
mucin
domain
member
immunoglobulin
superfamili
gain
entri
host
cell
postentri
translat
positivesens
rna
genom
host
ribosom
machineri
mediat
via
presenc
intern
ribosom
entri
site
ire
encod
region
utr
viral
rna
result
product
larg
viral
polyprotein
polyprotein
cleav
structur
nonstructur
protein
well
intermedi
etc
virallyencod
proteas
pro
follow
cleavag
event
viral
rna
replicas
synthes
minussens
strand
correspond
viral
rna
genom
serv
templat
product
multipl
plussens
strand
meanwhil
structur
protein
assembl
form
virion
packag
major
plussens
rna
gener
replic
two
specif
cleavag
event
result
gener
matur
infecti
virion
precursor
cleavag
junction
cleavag
virion
subsequ
releas
apic
membran
infect
hepatocyt
entri
hepat
c
viru
hcv
target
host
cell
multistep
event
requir
sever
host
compon
cellular
receptor
surfac
molecul
thought
involv
process
includ
ctype
lectin
liver
lymph
nodespecif
integrin
lsign
dendrit
cell
dc
specif
intercellular
adhes
grab
nonintegrin
dcsign
glycosaminoglycan
gag
claudin
bind
cellular
receptor
primarili
mediat
viral
envelop
protein
postentri
viru
nucleocapsid
disassembl
releas
plussens
rna
genom
cell
cytosol
act
templat
mediat
translat
singl
hcv
polyprotein
gener
translat
like
correspond
hav
polypeptid
also
undergo
proteas
mediat
coand
postprocess
yield
entir
repertoir
viral
structur
nonstructur
protein
hcv
infect
membran
web
form
site
rna
replic
mediat
translat
postprocess
event
endoplasm
reticulum
er
serv
site
format
viral
nucleocapsid
envelop
format
final
viru
matur
occur
golgi
matur
virion
exocytos
extracellular
space
life
cycl
hepat
e
viru
hev
well
understood
primarili
due
nonavail
appropri
cell
cultur
system
studi
shown
possibl
involv
heat
shock
cognat
protein
heparan
sulfat
proteoglycan
hspg
initi
attach
hev
target
cell
final
entri
mediat
yet
unknown
receptor
sever
host
factor
glucoseregul
protein
heat
shock
protein
also
thought
involv
viral
entri
capsid
uncoat
rna
genom
releas
cytosol
close
follow
translat
viral
open
read
frame
orf
encod
entir
nonstructur
cassett
multipl
copi
synthesi
positivesens
rna
genom
mediat
virusencod
rnadepend
rna
polymeras
via
negativesens
rna
intermedi
viral
encod
capsid
protein
associ
progeni
viral
genom
form
nucleocapsid
follow
intracellular
transport
releas
matur
virion
postul
viral
encod
protein
involv
intracellular
traffick
process
hbv
unlik
hepatotrop
virus
distinct
mechan
propag
within
host
cellular
entri
incom
particl
via
endocytosi
initi
interact
hspg
follow
sodium
taurochol
cotransport
polypeptid
ntcp
gain
access
cytosol
viru
travel
nuclear
pore
complex
dna
genom
releas
nucleu
partial
doublestrand
dna
genom
subsequ
convert
coval
close
circular
dna
cccdna
form
associ
histon
nuclear
protein
within
nucleu
transcript
event
lead
product
mrna
encod
revers
transcriptas
nucleocapsid
pregenom
addit
transcript
encod
surfac
antigen
subgenom
also
produc
preand
subgenom
transcrpit
transfer
cytosol
surfac
protein
synthesi
gener
core
subvir
particl
occur
er
translat
product
viral
polymeras
core
protein
pregenom
rna
associ
protein
kinas
pk
hsp
pregenom
rna
yield
matur
core
particl
either
releas
infect
cell
recircul
nucleu
maintain
cccdna
level
interestingli
subvir
particl
releas
via
secretori
pathway
involv
golgi
er
matur
core
particl
releas
multivesicular
particl
although
much
known
regard
cellular
entri
process
hepat
viru
hdv
studi
suggest
similar
hbv
entri
pathway
involv
interact
hspg
ntcp
viral
larg
hepat
b
surfac
antigen
lhbsag
domain
postentri
transfer
rna
genom
nucleu
facilit
virallyencod
hepat
antigen
hdag
within
nucleu
host
rna
polymeras
initi
genom
replic
proce
via
roll
circl
mechan
subsequ
transcript
translat
event
lead
product
larg
delta
antigen
undergo
prenyl
prior
associ
progeni
viral
genom
subsequ
assembl
viral
releas
requir
assist
hbv
current
treatment
scenario
hav
current
specif
treatment
option
avail
hav
infect
individu
usual
receiv
symptomat
treatment
liver
transplant
viabl
option
case
fhf
vaccin
inactiv
hav
virion
fairli
effect
confer
protect
preval
strain
viru
found
human
popul
vaccin
attenu
virion
also
employ
met
limit
success
spite
activ
vaccin
effort
howev
number
clinic
case
hav
report
quit
high
million
worldwid
hcv
due
mostli
asymptomat
natur
acut
hcv
infect
treatment
option
limit
howev
studi
report
interferonbas
treatment
earli
stage
might
help
individu
exhibit
hcv
rna
antibodi
detect
level
blood
month
postinfect
consid
case
chronic
hcv
infect
combin
therapi
ribavirin
pegifna
pegyl
interferon
durat
either
six
month
one
year
accept
treatment
regimen
chronic
case
hcv
infect
howev
achiev
sustain
virolog
respons
svr
key
cure
observ
vari
genotyp
popul
western
european
patient
infect
hcv
genotyp
reportedli
achiev
higher
svr
north
american
patient
popul
svr
achiev
treatment
case
patient
infect
genotyp
observ
higher
gener
compar
genotyp
patient
svr
particular
genotyp
found
suscept
svr
directact
antivir
daa
telaprevir
boceprevir
firstwav
first
gener
target
hcv
serin
proteas
introduc
treat
infect
caus
hcv
genotyp
phase
iii
clinic
trial
patient
found
administr
telaprevir
boceprevir
conjunct
ribavirin
pegifna
triplecombin
effect
achiev
svr
rang
howev
treatment
regimen
come
set
disadvantag
includ
signific
sideeffect
costeffect
case
patient
advanc
fibrosi
sinc
follow
daa
approv
use
either
independ
combin
pegifna
andor
ribavirin
daa
sofosbuvir
nucleotid
analogu
b
simeprevir
proteas
inhibitor
c
daclatasvir
proteas
inhibitor
paritaprevir
proteas
inhibitor
e
ombitasvir
inhibitor
f
asunaprevir
proteas
inhibitor
g
grazoprevir
proteas
inhibitor
h
elbasvir
replic
complex
inhibitor
rate
svr
achiev
depend
combin
use
genotyp
presenc
resist
strain
diseas
sever
final
attempt
creat
effect
vaccin
hcv
success
till
date
due
extrem
sequenc
variat
viru
genom
hev
acut
hev
infect
immunocompet
individu
usual
culmin
spontan
clearanc
viru
certain
time
period
howev
sever
case
lead
decreas
liver
function
administr
ribavirin
found
help
prompt
clearanc
viru
inhibit
liver
damag
remain
unclear
ribavirin
intak
arrest
progress
toward
complet
liver
failur
fulmin
hepat
till
date
liver
transplant
appropri
donor
remain
choic
patient
treatment
transplant
patient
suffer
chronic
infect
hev
follow
cours
action
usual
undertaken
posttransplant
first
step
involv
reduct
immunosuppress
shown
clearanc
rate
unsuccess
next
step
usual
involv
monotherapi
ribavirin
initi
period
day
administr
pegifna
also
option
howev
due
mani
sideeffect
complic
solid
organ
transplant
recipi
patient
prefer
hev
infect
pregnant
women
associ
signific
complic
like
stillbirth
abort
prematur
distribut
matern
fetal
death
interestingli
signific
differ
exist
sever
complic
caus
hev
infect
divers
endem
popul
instanc
infect
typic
sever
outcom
pregnant
women
northern
india
follow
fairli
benign
cours
popul
egypt
western
countri
studi
suggest
poor
prenat
care
nutrit
may
constitut
major
contributori
factor
sever
outcom
select
popul
effort
ongo
develop
effect
vaccin
hev
current
promis
candid
trade
name
hecolin
phase
iv
clinic
trial
clinicaltrialsgov
databas
form
hepat
acut
infect
hbv
treat
symptomat
specif
treatment
regimen
exist
howev
patient
develop
acut
liver
failur
result
sever
hbv
infect
administ
oral
antihbv
medic
major
emphasi
far
treatment
chronic
infect
hbv
current
approv
drug
interferon
adult
children
nucleotidenucleosid
analogu
na
nucleosid
analogu
lamivudin
entecavir
emtricitabin
telbivudin
nucleotid
analogu
adefovir
tenofovir
due
high
barrier
develop
resist
tenofovir
entecavir
use
firstlin
drug
treatment
analogu
like
lamivudin
adefovir
telbivudin
prescrib
potent
drug
either
appropri
avail
due
fact
drug
either
low
barrier
resist
telbivudin
less
efficaci
adefovir
shown
develop
resist
longterm
usag
lamivudin
interferon
util
enhanc
host
antvir
immun
respons
therapeut
strategi
usual
involv
two
specif
rout
applic
chronic
hepat
b
chb
short
treatment
year
pegifn
na
ii
treatment
na
longterm
basi
pegifnbas
therapi
prescrib
period
week
patient
best
possibl
hbe
seroconvers
absenc
hbeag
serum
presenc
antihb
antibodi
order
obtain
offtreat
respons
combin
pegifn
na
like
lamivudin
telbivudin
recommend
low
offtreat
respons
former
due
recipi
develop
polyneuropathi
latter
hbeagposit
patient
undergo
serotyp
convers
antihb
treat
na
time
howev
possibl
defin
exactli
timespan
treatment
initi
sinc
base
time
taken
undergo
serotyp
convers
treatment
continu
postseroconvers
stabl
offtreat
respons
treat
individu
observ
treatment
continu
month
post
serotyp
convers
antihb
ii
second
strategi
appli
individu
undergo
seroconvers
hbvrelat
liver
cirrhosi
entecavir
tenofovir
use
howev
long
term
effect
use
drug
known
current
data
show
monotherapi
year
ensur
remiss
major
treat
patient
patient
undergo
liver
transplant
due
hbvrelat
hcc
decompens
liver
cirrhosi
undergo
pretransplant
treatment
regim
potent
na
high
resist
barrier
order
reduc
viral
dna
level
minimum
transplant
posttreat
combin
adefovir
andor
lamivudin
hepat
b
immunoglobulin
hbig
found
effect
graft
reject
rate
less
given
treatment
scenario
complic
associ
prevent
hbv
infect
prioriti
effect
vaccin
hbv
exist
administ
time
month
period
hdv
till
date
known
effect
therapeut
strategi
avail
treatment
either
acut
chronic
form
hdv
infect
studi
shown
longterm
treatment
pegifna
help
clearanc
viru
case
efficaci
similar
interferon
administ
combin
adefovir
thu
absenc
effect
antivir
therapi
liver
transplant
option
patient
suffer
liver
damag
due
chronic
infect
commerci
avail
vaccin
hdv
howev
vaccin
avail
hbv
use
prevent
coinfect
hbv
hdv
upon
uptak
cell
nucleosid
analogu
undergo
set
three
phosphoryl
event
produc
nucleosid
triphosph
lack
group
deoxyribos
sugar
inhibit
replic
process
chain
termin
stall
replicationassoci
polymeras
na
similar
mechan
action
distinct
essenti
bypass
phosphoryl
step
sever
drug
like
emtricitabin
lamivudin
tenofovir
entecavir
stavudin
abacavir
etc
avail
treatment
human
immunodefici
viru
hiv
sever
analogu
also
use
treatment
chronic
hbv
hcv
infect
mention
previou
section
effect
inhibitor
includ
favipiravir
success
inhibit
negativeand
positivesens
rna
virus
approv
treatment
influenza
viru
japan
show
similar
inhibitori
effect
compound
signific
toxic
issu
sideeffect
due
replic
inhibit
primarili
nonspecif
addit
resist
phenotyp
often
encount
decreas
treatment
efficaci
b
nonna
polymeras
inhibitor
hand
target
bind
site
activ
site
viral
polymeras
induc
conform
chang
lead
downregul
activ
class
revers
transcriptas
inhibitor
like
nevirapin
delavirdin
efavirenz
well
known
primarili
inhibit
replic
bind
subunit
heterodimer
complex
nomenclatur
base
structur
organ
hcv
ii
proteas
play
essenti
role
life
cycl
mani
virus
make
essenti
target
inhibitor
design
hiv
proteas
cleav
viral
polyprotein
individu
compon
inhibit
proteas
effect
block
viral
replic
current
unit
state
food
drug
administr
approv
sever
inhibitor
drug
belong
categori
name
saquinavir
atazanavir
darunavir
fosamprenavir
indinavir
nelfinavir
lopinavir
ritonavir
tipranavir
inhibitor
serin
proteas
hcv
boceprevir
telaprevir
use
initi
usag
discontinu
sinc
effect
treatment
regimen
simeprevir
asunaprevir
paritaprevir
avail
mention
earlier
herein
sever
like
proteas
exist
picornavirus
coronavirus
norovirus
fact
rupintrivir
irrevers
proteas
inhibitor
origin
design
treat
rhinoviru
infect
also
display
inhibitori
activ
mention
viru
famili
lastli
treatment
regimen
usual
involv
combin
therapi
due
chanc
emerg
resist
phenotyp
iii
cyclophilin
cypa
belong
ubiquit
hostencod
protein
famili
peptidylprolyl
cistransisomeras
help
fold
traffick
host
protein
cypa
found
interact
nonstructur
protein
hcv
capsid
protein
hiv
present
two
drug
inhibit
cypa
name
alisporivir
use
drug
deriv
origin
immunosuppress
drug
sanglifehrin
cyclosporin
iv
sinc
host
lipid
metabol
essenti
viral
replic
compound
specif
alter
process
found
inhibit
viral
infect
perhap
notabl
class
inhibitor
statin
block
cholesterol
biosynthesi
obstruct
activ
coenzym
howev
although
class
inhibitor
shown
posit
result
vitro
sever
pathogen
like
hiv
hcv
signific
contradict
encount
vivo
studi
indol
deriv
arbidol
interfer
viru
membran
fusion
entri
envelop
virus
although
approv
china
russia
treat
respiratori
pathogen
like
influenza
viru
vitro
data
hbv
chikungunya
hcv
appear
encourag
data
relat
vivo
efficaci
drug
lack
anoth
lipid
modul
induc
membran
lipid
oxid
interfer
viru
membran
fusion
found
fairli
effect
envelop
virus
influenza
filovirus
hiv
poor
physiolog
stabil
requir
light
optim
activ
make
rather
unsuit
develop
deriv
sinc
produc
improv
characterist
squalamin
compound
interact
host
membran
alter
cellular
microenviron
make
unsuit
viru
propag
compound
also
success
phase
ii
trial
retin
vasculopathi
cancer
warrant
develop
sever
new
target
identifi
hbv
inhibitor
design
mani
present
differ
stage
develop
clinic
trial
includ
potent
polymeras
inhibitor
entri
inhibitor
cccdna
inhibitor
nucleocapsid
assembl
inhibitor
inhibitor
viral
gene
express
hbsag
releas
inhibitor
equal
effect
safer
deriv
tenofovir
entecavir
tenofovir
alafenamid
besofovir
shown
promis
result
random
phase
iii
trial
respect
bone
renal
safeti
profil
besofovir
anoth
drug
test
altern
entecavir
myrcludexb
engin
lipopeptid
effect
block
ntcp
receptor
entri
point
incom
hbv
virion
mous
model
studi
myrcludexb
shown
reduct
cccdna
level
viru
spread
phase
ii
clinic
trial
current
ongo
three
type
sitespecif
dna
bind
protein
engin
target
cccdna
zinc
finger
nucleas
zfn
transcript
activatorlik
effector
nucleas
talen
cluster
regulatori
interspac
short
palindrom
repeat
crispr
ca
endonucleas
vitro
studi
cell
shown
three
system
deactiv
cccdna
either
sitespecif
cleavag
introduc
frameshift
viral
orf
specif
disrupt
crisprca
disubstitut
sulphonamid
also
identifi
shown
prevent
format
cccdna
relax
circular
dna
vitro
compound
prevent
encapsid
viral
pregenom
rna
sulfamoylbenzamid
phenylpropenamid
deriv
also
constitut
attract
option
therapi
effect
naresist
wildtyp
hbv
inhibit
viral
gene
express
use
rna
interfer
rnai
attract
option
sinc
low
level
viral
antigen
allow
immun
system
recov
one
drug
develop
shown
promis
result
vitro
nucleic
acid
polym
rep
shown
abl
inhibit
releas
hbsag
infect
hepatocyt
vivo
studi
final
recent
studi
also
shown
hbv
rnaseh
critic
viru
replic
also
import
drug
target
case
hbv
novel
drug
target
identifi
hepatotrop
virus
well
tabl
viru
life
cycl
begin
infect
suitabl
host
order
make
multipl
copi
util
host
machineri
process
infect
gener
progeni
virion
execut
seri
well
coordin
step
involv
attach
entri
uncoat
replicationtranscriptiontransl
genet
materi
assembl
egress
viru
genom
encod
limit
number
protein
categor
primarili
structur
nonstructur
protein
structur
protein
gener
viru
capsid
nonstructur
protein
produc
infect
usual
part
capsid
recent
set
viral
protein
identifi
play
essenti
role
viru
life
cycl
primarili
abil
interact
penetr
cellular
membran
class
multifunct
protein
design
viroporin
form
pore
channel
cellular
membran
directli
indirectli
facilit
intracellular
surviv
viru
suggest
abil
viroporin
alter
ionic
concentr
remodel
host
cell
membran
enhanc
viral
uncoat
replic
egress
usual
viroporin
small
peptid
amino
acid
contain
one
transmembran
domain
format
pore
channel
cellular
membran
facilit
homooligomer
viroporin
oligomer
level
rang
dimer
associ
eg
hav
larg
heptamer
assembl
eg
hcv
till
date
sever
viroporin
identifi
function
character
envelop
nonenvelop
virus
fig
tabl
wellknown
exampl
influenza
viru
vpu
picornaviru
hcv
central
role
viroporin
facilit
sever
step
life
cycl
virus
suggest
class
viral
protein
promis
candid
develop
inhibitorbas
therapeut
fact
small
molecul
inhibitor
success
design
test
certain
viroporin
encourag
outcom
drug
amantadin
rimantadin
shown
effect
inhibit
ion
channel
activ
interestingli
sever
influenza
strain
specif
point
mutat
caus
resist
inhibitor
identifi
recent
mutat
like
affect
drug
bind
site
channel
alter
bind
pocket
hydrophob
overal
conform
channel
preval
point
mutat
identifi
strain
viru
attempt
current
made
synthes
inhibitor
resist
strain
use
deriv
inhibitor
although
novel
effect
deriv
obtain
sever
mutat
point
mutat
proven
difficult
gener
hexamethylen
amilorid
hma
deriv
eg
found
effect
block
vpu
channel
activ
thought
bind
channel
lumen
hma
deriv
current
undergo
clinic
trial
inhibitor
specif
till
date
resist
strain
report
coronavirusencod
e
peptid
also
effect
block
hma
observ
electrophysiolog
studi
use
cell
amantadin
also
capabl
inhibit
activ
effect
requir
significantli
higher
concentr
adamantan
alkyl
iminosugar
hma
identifi
hcv
blocker
base
protein
base
vitro
assay
howev
studi
report
inconsist
efficaci
data
preliminarili
due
genotypicsubtyp
differ
channel
even
though
compound
like
rimatadin
nnonyl
deoxynojirimycin
nndnj
exhibit
widespectrum
activ
amongst
genotyp
avail
high
resolut
structur
data
silico
dock
studi
help
unravel
mechan
action
inhibitor
nndnj
found
interfer
oligomer
via
interact
specif
phenylalanin
residu
th
posit
interestingli
inhibitori
activ
adamantan
found
due
bind
inhibitor
peripher
site
expos
membran
separ
nndnj
bind
site
dispar
bind
site
inhibitor
provid
possibl
use
combin
therapi
approach
treat
resist
strain
current
drug
develop
effort
typic
use
combin
ration
highthroughput
approach
result
identif
compound
resist
phenotyp
higher
potenc
minim
concentr
current
interest
pool
avail
data
lead
conclus
viroporinbas
therapeut
approach
subsequ
play
import
role
treat
clinic
case
envelop
virus
step
repres
attach
entri
uncoat
replic
assembl
egress
respect
nonenvelop
virus
step
repres
attach
entri
releas
intracellular
vesicl
uncoat
replic
assembl
egress
process
relev
human
pathogen
approach
toward
design
inhibitor
treatment
hcv
resist
phenotyp
also
extend
hepatotrop
virus
fact
recent
work
laboratori
character
membran
activ
capsid
compon
nonstructur
protein
hav
util
combin
biophys
studi
md
simul
electron
microscopi
shown
form
discreet
pore
nm
artifici
membran
data
thu
indic
membran
penetr
peptid
may
allow
hav
escap
endosom
gain
access
cellular
cytosol
potenti
critic
role
play
hav
entri
make
import
target
design
inhibitor
investig
nonstructur
protein
hav
found
contain
stretch
residu
cterminu
viroporinlik
activ
combin
crosslink
studi
biophys
assay
simul
employ
determin
probabl
form
dimer
gener
nm
pore
membran
result
alter
membran
permeabl
thought
essenti
hav
replic
probabl
inhibit
membran
activ
would
neg
impact
viral
replic
process
thu
treatment
regimen
hav
includ
combin
therapi
target
could
promis
effect
approach
given
essenti
role
play
viroporin
viral
membran
penetr
peptid
enhanc
sever
aspect
viru
life
cycl
target
inhibitor
therapi
hold
promis
develop
virusspecif
drug
establish
common
structur
function
membran
activ
compon
might
make
easier
design
small
molecul
inhibitor
final
given
promis
therapi
hcv
essenti
pinpoint
potenti
candid
hepatotrop
virus
order
expand
therapi
option
chronic
acut
viral
hepat
